Australian medtech start-up, 4Dx is a step closer to the integration of its visionary and breakthrough technology into everyday healthcare through its latest hardware sale to leading U.S. hospital, Cedars-Sinai Medical Center, a California nonprofit public benefit corporation.
Cedars-Sinai has received a grant award of US $600,000 from the United States National Institutes of Health for the purchase of 4Dx’s new preclinical lung scanner, making Cedars-Sinai the first institution scheduled to purchase this advanced instrument, which can help detect lung diseases in their early stages.
The new scanner addresses a dilemma of current antiquated technologies in measuring the impact of cystic fibrosis, asthma, COPD, emphysema and other disorders on the lung.
The 4Dx pre-clinical scanner generates high-resolution images of lung-tissue motion and airflow throughout the lungs, which allows investigators to view and measure defective functioning in specific areas of the lung, before a disease progresses and spreads.
What does this mean for 4Dx?
“Our game-changing diagnostic tool offers researchers images of the breathing lungs, making it possible to see what is really important – how they work, not what they look like,” says Andreas Fouras, Founder and CEO of 4Dx.
Cedars-Sinai and 4Dx will enter into a research collaboration using 4Dx’s scanner because “research collaboration with key leaders in the field is a major key to 4Dx’s ongoing success,” says Fouras.
“I have travelled the world speaking with doctors, practitioners and potential investors to find out what their concerns were, what excited them and what scared them,” he says.
In the U.S. there are 72.6 million diagnostic procedures every year, compared to 1 million in Australia, which represents an addressable market of US $25 billion per annum.
“Research collaboration with world leading researchers can be a key to market entry and a step forward on the pathway for the integration of 4Dx technology into everyday healthcare, where 4Dx can make a real difference to people’s lives.”
The revenue from this deal is a significant milestone for 4Dx as an early stage company and the collaboration will greatly assist 4Dx’s ongoing clinical validation in the US and Australia, and the clearance process from the US Food and Drug Administration (FDA), early next year.
Being associated with Cedars-Sinai is also a huge plus. Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research.
Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the United States, setting standards in quality and innovative patient care, research, teaching and community service.